A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

  • Autoimmune Disorder
  • Multiple Sclerosis (MS)
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Not yet recruiting

This study runs in
Cities
  • Charlottesville
  • Cleveland
  • Evanston
  • Great Neck
  • Irvine
  • La Jolla
  • Paramus
  • Pittsburgh
  • Portland
  • Saint Louis
  • Tampa
Trial Identifier:

NCT07008378 GN45773

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).

      Genentech, Inc. Sponsor
      Phase 1 Phase
      NCT07008378, GN45773 Trial Identifier
      P-CD19CD20-ALLO1 Cells, Cyclophosphamide, Fludarabine Treatments
      Multiple Sclerosis Condition
      Official Title

      A Phase I, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Patients With Multiple Sclerosis

      Eligibility Criteria

      All Gender
      ≥18 Years & ≤ 60 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Age 18-60 years (inclusive) at the time of signing Informed Consent Form
      • Diagnosis of progressive MS according to the revised McDonald 2017 criteria, and:

      Expanded disability status scale (EDSS) score at screening, from 3 to 6 inclusive Evidence of disability progression and no relapses in the 2 years prior to screening

      • Diagnosis of relapsing MS according to the revised McDonald 2017 criteria, and: Evidence of clinical relapses and MRI activity within two years prior to screening while on a disease modifying therapy
      • EDSS score at screening, from 0 to 6 inclusive
      • No relapses within 45 days of screening
      Exclusion Criteria
      • Pregnant or breastfeeding, or intention of becoming pregnant within the timeframe in which contraception is required
      • Participants who have confirmed or suspected Progressive Multifocal Leukoencephalopathy (PML)
      • Known or suspected history of Hemophagocytic Lymphohistiocytosis/ Macrophage Activation Syndrome (HLH/MAS) or neurotoxicity with prior therapies
      • Known presence of other neurologic disorders that may mimic MS
      • History of currently active primary or secondary (non-drug-related) immunodeficiency
      • Significant or uncontrolled medical disease which would preclude patient participation
      • High risk for clinically significant bleeding or any condition requiring plasmapheresis, IV Ig, or acute blood product transfusions
      • History of recurrent serious infections or chronic infection
      • Prior treatment with CAR T-cell therapy, gene-therapy product, total body irradiation, bone marrow transplantation, allograft organ transplant, or hematopoietic stem cell transplant at any point
      • Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate washout period.
      • Inability to complete an MRI scan

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now